الفهرس 
Title pageOnly 14 pages are availabe for public view
 |  | from | 145 |  |  |
| | | from | 145 | | |
Abstract
Fatty liver disorder is a quiet disease that, in its early stages, usually manifests itself by the absence of any symptoms. This disease may cause irreversible damage to the hepatic cells. Thus, the liver becomes dysfunctional and results in liver failure or hepatic cell carcinoma. The quantity of fat that is deposited in the liver has an effect on the inflammatory process. The current study is intended to measure the effect of hepatic fatty deposits on the 18F-FDG uptake used in the PET-CT scan and correlate that effect with the BMI. In our research.
patients were separated into two primary groups: non-fatty liver group: (25 patients) the control group with normal imaging features of liver tissue, Fatty liver group: (25 patients) with fatty liver (hepatic steatosis) based on the US and CT investigations, ALT, AST, GGT, FPG, TG were detected and FLI and HSI were calculated.
When comparing the fatty liver patients to the non-fatty liver patients, the data revealed a significant rise in the parameters of the PET-CT, including the SUVs, in the fatty liver group. The presence of hepatic markers did not appear to be associated with fat deposition in the liver.
FLI differed slightly between the studied groups, so it does not contribute to determining the uptake of fluorine-18-fluoro-deoxyglucose in liver tissues, the HSI of the fatty liver patients was substantially greater than that of the non-fatty liver patients in this study. The possibility of using the HSI of fatty liver degeneration in dividing patients into non-fatty liver patients and fatty liver patients.
The liver tissue uptake value has significant correlation with BMI which were observed in the non-fatty group only. We can use BMI to determine and predict liver uptake of 18F-FDG from the injected dose only in non-fatty liver patients.